Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge

PURPOSE: Pegaspargase (PEG-ASP) has largely replaced native Escherichia coli asparaginase (L-ASP) in the treatment of acute lymphoblastic leukemia because of its longer half-life and lower immunogenicity. Risk factors for allergic reactions to PEG-ASP remain unclear. Here, we identify risk factors f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Liu, Yiwei, Smith, Colton A., Panetta, John C., Yang, Wenjian, Thompson, Lauren E., Counts, Jacob P., Molinelli, Alejandro R., Pei, Deqing, Kornegay, Nancy M., Crews, Kristine R., Swanson, Hope, Cheng, Cheng, Karol, Seth E., Evans, William E., Inaba, Hiroto, Pui, Ching-Hon, Jeha, Sima, Relling, Mary V.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2019
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804844/
https://ncbi.nlm.nih.gov/pubmed/31188727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.02439
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars